Skip to main content
Premium Trial:

Request an Annual Quote

Packard to Sell Canberra, Expand Life Science Business

NEW YORK, Oct 31 – Packard BioScience said Tuesday it expects to complete the sale of its Canberra Industries subsidiary, a move that would allow the company to expand its life science business.

Mike Zebarth, a spokesman for Packard BioScience, confirmed that the proceeds from the sale would be used to step up the company’s life science efforts, however, he declined to comment on whether that would be done through acquisitions or organic growth.

He also declined to say how much he expected Canberra, a maker of instruments used to detect radioactive materials for the nuclear industry, to be sold for or who the potential buyer was.

Packard BioSciences’ other subsidiary, Packard Instrument, manufactures such products as microwell plate readers, imaging systems, bioanalytical spectrometers, and biochemicals.

Canberra will be accounted for as a discontinued operation in all periods represented in Packard’s upcoming earnings release.

The company also announced that its board of directors had elected Frank Witney to the offices of president and chief operating officer of Packard BioScience and President of the company's wholly-owned subsidiary, Packard Instrument Company. He will succeed Richard McKernan, who is retiring. Witney previously worked at Bio-Rad Laboratories.
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.